miR-590 is expressed at low levels in patients with atrial fibrosis and renal fibrosis, resulting in reduced suppression of the target gene TGFβR2 and activation of the TGFβ pathway[24, 25]. This evidence concerns the gene TGFB1 and renal fibrosis.